Business Description
R&G PharmaStudies Co Ltd
ISIN : CNE100005K44
Share Class Description:
SZSE:301333: Class ACompare
Compare
Traded in other countries / regions
301333.China IPO Date
2022-08-02Description
R&G PharmaStudies Co Ltd is a clinical trial outsourcing service provider. It offers full-chain clinical research outsourcing services, serving global pharmaceutical and medical device companies and scientific research institutions.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 17.22 | |||||
| Equity-to-Asset | 0.78 | |||||
| Debt-to-Equity | 0.06 | |||||
| Debt-to-EBITDA | 0.72 | |||||
| Interest Coverage | 40.65 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.3 | |||||
| Beneish M-Score | -1.27 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 11.2 | |||||
| 3-Year EBITDA Growth Rate | 17.4 | |||||
| 3-Year EPS without NRI Growth Rate | 10.3 | |||||
| 3-Year FCF Growth Rate | 104.6 | |||||
| 3-Year Book Growth Rate | 59.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 12.77 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 15.48 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.1 | |||||
| 9-Day RSI | 35.98 | |||||
| 14-Day RSI | 42.69 | |||||
| 3-1 Month Momentum % | 65.11 | |||||
| 6-1 Month Momentum % | 53.22 | |||||
| 12-1 Month Momentum % | -3.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.7 | |||||
| Quick Ratio | 4.55 | |||||
| Cash Ratio | 3.9 | |||||
| Days Inventory | 45.98 | |||||
| Days Sales Outstanding | 47.47 | |||||
| Days Payable | 36.57 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.36 | |||||
| Dividend Payout Ratio | 0.12 | |||||
| Forward Dividend Yield % | 0.36 | |||||
| 5-Year Yield-on-Cost % | 0.35 | |||||
| 3-Year Average Share Buyback Ratio | -10.1 | |||||
| Shareholder Yield % | -0.14 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 39.72 | |||||
| Operating Margin % | 14.51 | |||||
| Net Margin % | 15.96 | |||||
| FCF Margin % | 20 | |||||
| ROE % | 6.87 | |||||
| ROA % | 5.59 | |||||
| ROIC % | 24.65 | |||||
| 3-Year ROIIC % | 48.41 | |||||
| ROC (Joel Greenblatt) % | 270.24 | |||||
| ROCE % | 7.69 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 33.52 | |||||
| Forward PE Ratio | 30.55 | |||||
| PE Ratio without NRI | 34.2 | |||||
| Shiller PE Ratio | 50.27 | |||||
| Price-to-Owner-Earnings | 53.51 | |||||
| PEG Ratio | 5.52 | |||||
| PS Ratio | 6.46 | |||||
| PB Ratio | 2.99 | |||||
| Price-to-Tangible-Book | 3.17 | |||||
| Price-to-Free-Cash-Flow | 31.34 | |||||
| Price-to-Operating-Cash-Flow | 28.26 | |||||
| EV-to-EBIT | 27.91 | |||||
| EV-to-EBITDA | 27.91 | |||||
| EV-to-Revenue | 5.13 | |||||
| EV-to-FCF | 26.97 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.43 | |||||
| Price-to-Graham-Number | 2.2 | |||||
| Price-to-Net-Current-Asset-Value | 3.39 | |||||
| Price-to-Net-Cash | 4.37 | |||||
| Earnings Yield (Greenblatt) % | 3.58 | |||||
| FCF Yield % | 2.84 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
R&G PharmaStudies Co Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 758.631 | ||
| EPS (TTM) (Â¥) | 1.65 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 69.67 | ||
| 14-Day RSI | 42.69 | ||
| 14-Day ATR (Â¥) | 3.502857 | ||
| 20-Day SMA (Â¥) | 58.343 | ||
| 12-1 Month Momentum % | -3.07 | ||
| 52-Week Range (Â¥) | 33.05 - 73.08 | ||
| Shares Outstanding (Mil) | 96.58 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
R&G PharmaStudies Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
R&G PharmaStudies Co Ltd Stock Events
| Event | Date | Price (Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
R&G PharmaStudies Co Ltd Frequently Asked Questions
What is R&G PharmaStudies Co Ltd(SZSE:301333)'s stock price today?
The current price of SZSE:301333 is ¥55.30. The 52 week high of SZSE:301333 is ¥73.08 and 52 week low is ¥33.05.
When is next earnings date of R&G PharmaStudies Co Ltd(SZSE:301333)?
The next earnings date of R&G PharmaStudies Co Ltd(SZSE:301333) is .
Does R&G PharmaStudies Co Ltd(SZSE:301333) pay dividends? If so, how much?
The Dividend Yield %  of R&G PharmaStudies Co Ltd(SZSE:301333) is 0.36% (As of Today), Highest Dividend Payout Ratio of R&G PharmaStudies Co Ltd(SZSE:301333) was 0.15. The lowest was 0.12. And the median was 0.15. The  Forward Dividend Yield % of R&G PharmaStudies Co Ltd(SZSE:301333) is 0.36%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers